SHANGHAI and MOLNDAL, Sweden, July 22, 2026 /PRNewswire/ — Suzhou Ribo Life Science Co., Ltd.  (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") today announce at China Pharmaceutical Innovation Conference (CPIC) in Shanghai, the positive results from a Phase 2a study in Europe evaluating vortosiran (RBD4059), Ribo's siRNA therapy targeting coagulation Factor XI (FXI), in patients with chronic coronary artery disease (CAD).   The randomized, double-blind, placebo-controlled study demonstrated that vortosiran in patients receiving standard of care, aspirin, treatment was generally well tolerated and achieved profound, dose-dependent, and long-lasting suppression of FXI activity (NCT06717074, clinicaltrials.gov). Patients with chronic CAD with previous…